Clinical Trial Update: An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study [Phase 3]

View source ↗

Summary

Extension study of onartuzumab in participants with solid tumors previously treated in a sponsor study; completed Phase 3 trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Onartuzumab (onartuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Solid Tumor | Phase 3 | Status: COMPLETED | Results posted: 2019-07-23